Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06689670 | Needle-based Percutaneous Ablation of Liver Tumors. | recruiting | N/A | 31 | inTumo Therapeutics, Inc.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07314372 | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma(FAD-HCC-001) | not yet recruiting | Phase 2 | 86 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 20, 2026 |
| clinicaltrials |
| NCT07351513 | A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 94 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07324824 | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma | recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06405321 | Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma | recruiting | — | 2,000 | Guangxi Medical UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06635694 | naVIGation Invitations Liver surveillANce upTake(VIGILANT) | active not recruiting | — | 652 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07341321 | SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors(CoVaCheck) | not yet recruiting | — | 200 | Medical University of GrazOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07337031 | A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer | not yet recruiting | N/A | 193 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337421 | Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337460 | Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04573881 | The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)(#HOPE4LIVER) | active not recruiting | N/A | 24 | HistoSonics, Inc.INDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT03894917 | Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma | recruiting | — | 84 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | recruiting | Phase 2 | 141 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07297654 | First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment(FINELAND) | not yet recruiting | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07324304 | NWRD06 DNA Plasmid for HCC After Curative Resection. | recruiting | Phase 2 | 30 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | not yet recruiting | Phase 2 | 65 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06526104 | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07321067 | Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes(ICIs) | not yet recruiting | — | 75 | Ahmed Karam HelmyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 158 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06590246 | A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 121 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07315633 | An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer | recruiting | — | 80 | University Hospital, GhentOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | active not recruiting | Phase 3 | 687 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma(Cocktail-001) | not yet recruiting | Phase 2 / Phase 3 | 222 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310173 | Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 75 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07310836 | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation | not yet recruiting | — | 300 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07306481 | The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer | not yet recruiting | N/A | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06828380 | A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion(IOPT) | recruiting | Phase 2 | 128 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07303712 | Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 | recruiting | — | 12 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04587739 | Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.(KARCHER-1) | recruiting | Phase 1 | 30 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07298538 | Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer | active not recruiting | — | 800 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06218511 | A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) | active not recruiting | Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06523608 | Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease(DETECT) | recruiting | — | 600 | University Hospital MuensterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07291141 | A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis(DETECT-HCC) | recruiting | — | 600 | Mattias EkstedtOTHER_GOV | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 300 | Polaris GroupINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | recruiting | Phase 1 | 70 | Myeloid TherapeuticsINDUSTRY | 3 | Dec 18, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07282184 | Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention | recruiting | Phase 1 / Phase 2 | 144 | Tongji HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07290764 | Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy | enrolling by invitation | — | 729 | Fujian Provincial HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05263830 | Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy(IMMUNOGLYPIC) | recruiting | — | 240 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT07285850 | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD(ABATE-MASLD) | recruiting | Phase 2 / Phase 3 | 20 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06537908 | Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC | recruiting | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06676982 | Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 12 | Zhejiang UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281664 | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 30 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials